To determine whether TAUT is broadly required for de novo AML growth, we tested the impact of its loss on initiation of leukaemia driven by MLL-AF9/NRAS(G12V) and by AML-ETO9a/NRAS(G12V). This evidence concerns the gene MLLT3 and acute myeloid leukemia.